Kimberly J Johnson1, Xiaoyan Wang2, Justin M Barnes3, Arash Delavar4. 1. Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA. kijohnson@wustl.edu. 2. Brown School, Washington University in St. Louis, One Brookings Drive, Campus Box 1196, St. Louis, MO, 63130, USA. 3. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 4. University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Abstract
PURPOSE: Prior research shows that residential distance to a treatment facility may be an important factor in central nervous system (CNS) tumor outcomes. Our goal was to examine residential distance to the reporting hospital and overall survival in adolescents and young adults (AYA) diagnosed with CNS tumors. METHODS: National Cancer Database data on AYA 15-39 years old diagnosed with CNS and Other Intracranial and Intraspinal Neoplasms (CNS tumors) from 2010 to 2014 were obtained. Distance between the case's residence at diagnosis or initial treatment and the reporting hospital was classified in miles as short (≤ 12.5), intermediate (> 12.5 and < 50), and long (≥ 50). Cox proportional hazards regression models were used for analyses. RESULTS: Among 9335 AYA diagnosed with CNS tumors, hazard ratios (HRs) were 1.06 (95% CI 0.96-1.17) and 0.82 (95% CI 0.73-0.93) for those with residences at intermediate and long vs. short distances, respectively, after adjusting for age, sex, race/ethnicity, and zip-code level education and income. After adjusting for the facility volume of CNS tumor patients, the association was attenuated for long vs. short distance residences (HR 0.92, 95% CI 0.81-1.04). The HRs varied by tumor type, race/ethnicity, and zip-code level income with significantly lower hazards of death for those with residences at long vs. short distances for low-grade astrocytic tumors, ependymomas, non-Hispanic Whites, and those from higher-income areas. CONCLUSIONS: Living at long distances for CNS tumor care may be associated with better survival in AYA patients. This may be explained by travel to facilities with more experience treating CNS tumors.
PURPOSE: Prior research shows that residential distance to a treatment facility may be an important factor in central nervous system (CNS) tumor outcomes. Our goal was to examine residential distance to the reporting hospital and overall survival in adolescents and young adults (AYA) diagnosed with CNS tumors. METHODS: National Cancer Database data on AYA 15-39 years old diagnosed with CNS and Other Intracranial and Intraspinal Neoplasms (CNS tumors) from 2010 to 2014 were obtained. Distance between the case's residence at diagnosis or initial treatment and the reporting hospital was classified in miles as short (≤ 12.5), intermediate (> 12.5 and < 50), and long (≥ 50). Cox proportional hazards regression models were used for analyses. RESULTS: Among 9335 AYA diagnosed with CNS tumors, hazard ratios (HRs) were 1.06 (95% CI 0.96-1.17) and 0.82 (95% CI 0.73-0.93) for those with residences at intermediate and long vs. short distances, respectively, after adjusting for age, sex, race/ethnicity, and zip-code level education and income. After adjusting for the facility volume of CNS tumor patients, the association was attenuated for long vs. short distance residences (HR 0.92, 95% CI 0.81-1.04). The HRs varied by tumor type, race/ethnicity, and zip-code level income with significantly lower hazards of death for those with residences at long vs. short distances for low-grade astrocytic tumors, ependymomas, non-Hispanic Whites, and those from higher-income areas. CONCLUSIONS: Living at long distances for CNS tumor care may be associated with better survival in AYA patients. This may be explained by travel to facilities with more experience treating CNS tumors.
Authors: R R G Knops; E C van Dalen; R L Mulder; E Leclercq; S L Knijnenburg; G J L Kaspers; R Pieters; H N Caron; L C M Kremer Journal: Ann Oncol Date: 2013-02-01 Impact factor: 32.976
Authors: Christian Lopez Ramos; Michael G Brandel; Jeffrey A Steinberg; Arvin R Wali; Robert C Rennert; David R Santiago-Dieppa; Reith R Sarkar; J Scott Pannell; James D Murphy; Alexander A Khalessi Journal: J Neurooncol Date: 2018-11-20 Impact factor: 4.130
Authors: Kimberly D Miller; Miranda Fidler-Benaoudia; Theresa H Keegan; Heather S Hipp; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2020-09-17 Impact factor: 508.702
Authors: Leila T Tchelebi; Biyi Shen; Ming Wang; Niraj J Gusani; Vonn Walter; Ross Abrams; Vivek Verma; Nicholas G Zaorsky Journal: Cancer Date: 2021-08-16 Impact factor: 6.860
Authors: Nader N Massarweh; Yi-Ju Chiang; Yan Xing; George J Chang; Alex B Haynes; Y Nancy You; Barry W Feig; Janice N Cormier Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Justin M Barnes; Kimberly J Johnson; Jeremy L Grove; Amar J Srivastava; Nosayaba Osazuwa-Peters; Stephanie M Perkins Journal: Cancer Date: 2021-10-25 Impact factor: 6.860